BioShield Bill Creates “Emergency Use Authority” Tied To Monetary Penalties
Executive Summary
FDA could license bioterrorism countermeasures for "emergency use" with the legal backing of monetary penalties to ensure companies comply with the agency's terms under the Senate's "BioShield" bill
You may also be interested in...
BioShield Should Extend Liability Protection To Unapproved Products – BIO
Liability protections under "Project BioShield" should be extended to companies that make unapproved bioterrorism countermeasures available in an emergency situation, the Biotechnology Industry Organization said
BioShield Should Extend Liability Protection To Unapproved Products – BIO
Liability protections under "Project BioShield" should be extended to companies that make unapproved bioterrorism countermeasures available in an emergency situation, the Biotechnology Industry Organization said
“Project BioShield”: Industry Has Concerns, FDA Offers Support
A "Project BioShield" provision that would allow government funding only for bioterrorism countermeasures for which no commercial market exists is understood to be a concern among pharmaceutical and biotech companies
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: